Cantor Fitzgerald Downgrades RA Medical Systems (NYSE:RMED) to Neutral
Cantor Fitzgerald cut shares of RA Medical Systems (NYSE:RMED) from an overweight rating to a neutral rating in a research report released on Tuesday, The Fly reports. Cantor Fitzgerald currently has $2.00 price objective on the stock, down from their previous price objective of $10.00.
Several other research analysts have also weighed in on RMED. Piper Jaffray Companies lowered shares of RA Medical Systems from an overweight rating to a neutral rating and reduced their price objective for the stock from $9.00 to $1.50 in a research note on Tuesday. Maxim Group reduced their price objective on shares of RA Medical Systems to $12.00 and set a buy rating on the stock in a research note on Wednesday, May 15th. Finally, Zacks Investment Research raised shares of RA Medical Systems from a sell rating to a hold rating in a research note on Wednesday, July 17th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. RA Medical Systems currently has an average rating of Hold and a consensus price target of $6.38.
RA Medical Systems stock opened at $1.80 on Tuesday. The company’s 50 day simple moving average is $2.93 and its 200 day simple moving average is $4.31. RA Medical Systems has a fifty-two week low of $1.09 and a fifty-two week high of $22.00. The firm has a market capitalization of $15.64 million and a price-to-earnings ratio of -0.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 11.89 and a quick ratio of 11.45.
A number of hedge funds have recently made changes to their positions in RMED. Envestnet Asset Management Inc. acquired a new stake in RA Medical Systems during the 2nd quarter worth approximately $45,000. Weil Company Inc. acquired a new stake in RA Medical Systems during the 2nd quarter worth approximately $63,000. BlackRock Inc. raised its holdings in RA Medical Systems by 94.2% during the 2nd quarter. BlackRock Inc. now owns 22,438 shares of the company’s stock worth $81,000 after buying an additional 10,883 shares during the period. Dowling & Yahnke LLC acquired a new stake in RA Medical Systems during the 2nd quarter worth approximately $110,000. Finally, Meitav Dash Investments Ltd. raised its holdings in RA Medical Systems by 18.8% during the 1st quarter. Meitav Dash Investments Ltd. now owns 118,260 shares of the company’s stock worth $415,000 after buying an additional 18,741 shares during the period. Hedge funds and other institutional investors own 20.13% of the company’s stock.
About RA Medical Systems
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Further Reading: What is the significance of the death cross?
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.